Ciprofloxacin

Ciprofloxacin is a fluoroquinolone antibiotic, one of the most widely used members of that class. It has a broad spectrum of activity and is particularly effective against Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Haemophilus influenzae, while being comparatively weaker against many Gram-positive organisms. It is available in several forms, including immediate-release and extended-release oral tablets, an intravenous solution, and eye and ear drops.

The drug was developed by Bayer, patented around 1980 and introduced later in the decade, as an improvement on earlier quinolones such as norfloxacin. It is used for urinary and respiratory tract infections, certain gastrointestinal infections, bone and joint and skin infections, enteric fever, and post-exposure prophylaxis for anthrax, among other indications.

Much contemporary discussion of ciprofloxacin centers on resistance. Because it has been used heavily, including for minor infections that older narrow-spectrum drugs could treat, many bacteria have evolved resistance; this arises mainly through mutations in the quinolone-resistance-determining regions of the target enzymes and through plasmid-mediated mechanisms, and it has spread in organisms such as Salmonella, reducing the drug's reliability for typhoid and related infections ^[1][2].

Ciprofloxacin also carries significant safety warnings. Regulators have attached boxed warnings for tendinitis and tendon rupture, and observational studies confirm a real if uncommon increase in Achilles tendon rupture among users, with the risk raised further by older age and corticosteroid use ^[3][4]. Other recognized harms include potentially long-lasting peripheral neuropathy, central nervous system effects, QT-interval prolongation, and a possible association with aortic aneurysm, which is why authorities now advise reserving fluoroquinolones for situations without suitable alternatives. It is a prescription-only medicine.

Ciprofloxacin is prescription only. Common side effects include nausea, diarrhea, and headache. It carries serious boxed warnings for tendinitis and tendon rupture (often the Achilles), peripheral nerve damage, and worsening of myasthenia gravis, and it has been linked to aortic aneurysm and tears. It can prolong the QT interval, trigger seizures or confusion, cause photosensitivity, and set off Clostridioides difficile colitis. Antacids and products with calcium, magnesium, iron, or zinc bind the drug and block its absorption, so separate them by several hours. It raises levels of tizanidine (contraindicated) and theophylline and can potentiate warfarin, so those combinations need care.

Ciprofloxacin is a potent CYP1A2 inhibitor, and that sets it apart from the newer fluoroquinolones. Tizanidine is the extreme case: co-administration raises tizanidine exposure roughly tenfold with marked hypotension and sedation, and the combination is contraindicated. Theophylline levels climb far enough to cause seizures, and clozapine, olanzapine, duloxetine, ropinirole and caffeine all accumulate by the same route.

Absorption is the other reliable problem. Antacids containing aluminum or magnesium, iron and zinc salts, calcium, sucralfate and dairy products chelate ciprofloxacin in the gut and can strip most of a dose before it is absorbed, turning a treatable infection into a failed course.

Beyond that it carries the class hazards. Ciprofloxacin prolongs QT and adds to other QT-prolonging drugs; INR rises have been reported on warfarin; NSAIDs increase CNS stimulation and seizure risk; corticosteroids raise the risk of tendinitis and tendon rupture, particularly past 60; and hypoglycemia has been reported with glyburide. It also slows methotrexate clearance, which raises methotrexate toxicity.

Checking a whole stack? Run it through interactions + stacks.

Ciprofloxacin was synthesized in 1981 by chemists at Bayer AG in Germany, with Klaus Grohe credited for its discovery; it grew out of the fluoroquinolone research program that improved on the older quinolone nalidixic acid by adding a fluorine atom and a piperazine ring for far broader activity. Bayer secured patents in the early 1980s, and the drug reached the United States market in 1987 under the brand Cipro.

Through the 1990s it became one of the world's most prescribed antibiotics, prized for oral, broad-spectrum coverage of Gram-negative organisms and excellent tissue penetration. It gained wide public attention in 2001 as a frontline prophylaxis during the United States anthrax mailings, driving a surge in demand. Ciprofloxacin appears on the World Health Organization list of essential medicines, though class-wide safety reviews later led regulators to add strong warnings covering tendon injury, peripheral neuropathy, central nervous system effects, and aortic risk.

Ciprofloxacin is regarded as a landmark antibiotic and remains a clinical workhorse where potent Gram-negative activity is needed, including many urinary, prostatic, gastrointestinal, and bone infections. Clinicians value its high oral bioavailability, which is strong enough that oral dosing often rivals intravenous therapy, along with its deep tissue distribution. Its standing has become more nuanced over time; the same class properties that make it powerful are linked to characteristic connective-tissue and neurological effects, so guidelines now reserve it for situations where its benefits clearly outweigh those risks. Rising bacterial resistance, particularly among enteric organisms such as Salmonella, has also narrowed some of its historic uses. Even so, it endures as an essential medicine and a reference point against which newer agents are measured.